Kiniksa expects 2025 ARCALYST net product revenue of between $560 million and $580 million. As of December 31, 2024, Kiniksa had $243.6 million of cash, cash equivalents, and short-term investments ...
Company to present at 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 AM PST / 4:15 PM GMT (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, ...
CAR-T cell therapy, a marvel of bioengineering, takes a patient’s own immune cells and reprograms them to attack cells causing Lupus. First approved for treating leukemia in 2017, CAR-T cell therapy ...